TBX21 and mature T-cell and NK-cell non-Hodgkin lymphoma: In contrast, PTCL-TBX21 is characterized by NFKB pathway activation, fewer genomic abnormalities, and a more favorable prognosis, with a 5-year overall survival rate of 38% [40].